During deregulation talks in March, Clinton administration trade officials urged members of Japan’s Ministry of Health and Welfare in Tokyo to expedite the process by which American companies sell new and improved medical equipment.As part of last
During deregulation talks in March, Clinton administration trade officials urged members of Japans Ministry of Health and Welfare in Tokyo to expedite the process by which American companies sell new and improved medical equipment.
As part of last years U.S.-Japan deregulation agreement, Japan agreed to improve its approval and reimbursement system for new and existing medical technology.
Japan implemented some of the reforms, but not others, said Linda Ruckel, HIMA spokeswoman. In Marchs round of deregulation talks, HIMA urged Japanese officials to finish the remaining reforms.
Manufacturers of diagnostic imaging platforms such as MR, CT, and ultrasound enjoy success in Japan because hospitals can put out bids for equipment through a procurement process set up in the 1980s, said Paul Barry, HIMAs associate vice president of global strategy and analysis.
But if a U.S. company improves a heart catheter or any type of orthopedic or in vitro diagnostic equipment, the manufacturer must wait for Japans national health insurance system to create a new category for the equipment. The system is run by the Ministry of Health and Welfare.
Currently, new technology can be introduced in the Japanese market only on April 1 every two yearswith rare exceptions. The Japanese government will not provide reimbursement coverage for improved versions of existing medical technology for months or even years.
You might gain a safety approval, but no reimbursement, Barry said.
Japans trade policy affects medical equipment companies such as Johnson & Johnson, Boston Scientific, Medtronic, St. Jude, and Smith & Nephew, Barry said.
U.S. companies supply approximately 25% of the $23.4 billion in medical technologies used by the Japanese. By comparison, U.S. medical technology companies hold a 40% to 50% market share in other foreign countries, according to HIMA.
This ultimately hurts Japans patients and providers, who lack access to the latest medical innovations, said Pamela Bailey, HIMAs president.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.